Because sTNFR1, IL8, and Ang2 reflect pathways that are dysregulated in sepsis and for which therapies are being investigated, such as monoclonal antibodies targeting IL8 and TNF [16–18], they should be evaluated as predictive enrichment factors for their designated therapies in future trials. This evidence concerns the gene TNF and Sepsis.